Aclarion, Inc., (ACON): Price and Financial Metrics

Aclarion, Inc., (ACON): $0.30

0.00 (0.73%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

F

Add ACON to Watchlist
Sign Up

Industry: Medical - Services

Industry

D

Ranked

#68 of 69

in industry

ACON Price/Volume Stats

Current price $0.30 52-week high $21.60
Prev. close $0.30 52-week low $0.27
Day low $0.29 Volume 125,600
Day high $0.30 Avg. volume 2,368,861
50-day MA $0.31 Dividend yield N/A
200-day MA $3.06 Market Cap 2.48M

ACON Stock Price Chart Interactive Chart >


Aclarion, Inc., (ACON) Company Bio


Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.


ACON Latest News Stream


Event/Time News Detail
Loading, please wait...

ACON Latest Social Stream


Loading social stream, please wait...

View Full ACON Social Stream

Latest ACON News From Around the Web

Below are the latest news stories about ACLARION INC that investors may wish to consider to help them evaluate ACON as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!

William White on InvestorPlace | December 21, 2023

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of scan volumes expected as MRIs are activated for the recently completed panel of 10 Key Opinion Leader (KOL) surgeons All commercial Nociscans to date have been completed on Siemens MRI scanners with additional acceleration of volumes expected as Philips scanners are onboarded BROOMFIELD, CO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or th

Yahoo | November 27, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

William White on InvestorPlace | November 17, 2023

Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption

Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low back pain is a critical step to establishing Nociscan as standard of care. Aclarion’s KOL panel represents spine surgeons at some of the largest and most influential academic centers and private practices in the country, including leaders of national societies that advocate for protocols to improve clinical treatments. The Company intends to activate MRIs for each KOL sur

Yahoo | November 8, 2023

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and the co-director of New York-Presbyterian Och Spine. Dr. Hartl becomes Aclarion’s 2nd KOL to get access to an MRI center authorized to perform Nociscans, adding NYC to Denver as the second active KOL site. Aclarion will report on Nociscan volumes to date before the end of the year and add this key metric to quarterly reporting beginning in

Yahoo | November 6, 2023

Read More 'ACON' Stories Here

ACON Price Returns

1-mo 4.53%
3-mo -25.00%
6-mo -91.10%
1-year -98.55%
3-year N/A
5-year N/A
YTD -90.63%
2023 -65.52%
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!